Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, and Adamas Pharmaceuticals Inc., have announced an agreement for Phase III clinical trials manufacturing of ADS-5102 (amantadine HCl) extended release capsules, an investigational treatment being developed for Levodopa-Induced Dyskinesia (LID) in patients with Parkinson’s disease.

“We believe Catalent’s capabilities make them the right choice to support execution of our upcoming clinical trials,” said Gregory T. Went, PhD, Adamas Chairman and Chief Executive Officer. 

Barry Littlejohns, President of Catalent’s Advanced Delivery Technologies business said: “Our controlled release formulation expertise and drug delivery technologies will ultimately benefit patients with better treatments. We are pleased Adamas selected Catalent for the development and supply of ADS-5102 which, if approved, will be the first medical treatment indicated for patients with LID in Parkinson’s disease.” 

Information source：http://www.cphi-online.com/News/Show/17960/Catalent_and_Adamas_Pharmaceuticals_Enter_Phase_III_Clinical_Trials_Manufacturing_Agreement#.Us96l7Ldglk